What is the recommended target range for intact parathyroid hormone (iPTH) in a patient with chronic kidney disease (CKD) stage 4 (estimated glomerular filtration rate 15–29 mL/min/1.73 m²)?

Recommended iPTH Target for CKD Stage 4

For patients with CKD Stage 4, maintain intact PTH levels between 70-110 pg/mL (approximately 1.5-2.5 times the upper limit of normal for the assay). 1

Target Range Rationale

The K/DOQI guidelines explicitly define target ranges for iPTH based on CKD stage, with Stage 4 (GFR 15-29 mL/min/1.73 m²) requiring iPTH levels of 70-110 pg/mL. 1 This range is deliberately set above the normal reference range (typically <65 pg/mL) because maintaining "normal" PTH levels in CKD patients leads to adynamic bone disease—a low-turnover bone disorder associated with increased fracture risk and vascular calcification. 1

Monitoring Frequency

• Measure iPTH at least once initially when GFR falls below 30 mL/min/1.73 m² 2
• If calcium and/or phosphorus levels are abnormal, monitor iPTH every 3 months 2
• Measure serum calcium and phosphorus at least every 3 months 1, 2
• Check 25-hydroxyvitamin D at first encounter if iPTH is elevated; repeat annually if normal 1

Management Algorithm When iPTH Exceeds Target

Step 1: Evaluate and Correct Modifiable Factors

When iPTH rises above 110 pg/mL, systematically address: 1, 2

• Hyperphosphatemia: Target phosphorus 2.7-4.6 mg/dL in Stage 4 CKD 1

  • Initiate dietary phosphorus restriction to 800-1,000 mg/day 1
  • Add phosphate binders if dietary restriction fails after 1 month 2
  • Limit elemental calcium from binders to ≤1,500 mg/day 1

• Vitamin D insufficiency: If 25(OH)D <30 ng/mL 1

  • Prescribe ergocalciferol (vitamin D2) per dosing table in guidelines 1
  • Continue supplementation with vitamin D-containing multivitamin once replete 1

• Hypocalcemia: If corrected total calcium <8.4 mg/dL 1

  • Provide elemental calcium 1 g/day between meals or at bedtime (after addressing phosphorus) 2
  • Total calcium intake (dietary + supplements) should not exceed 2,000 mg/day 1

Step 2: Active Vitamin D Therapy

If iPTH remains >300 pg/mL despite correcting the above factors, initiate active vitamin D sterol therapy (calcitriol, alfacalcidol, paricalcitol, or doxercalciferol). 1

Prerequisites for starting active vitamin D: 1

• 25(OH)D levels >30 ng/mL 1
• Corrected total calcium <9.5 mg/dL 1
• Serum phosphorus <4.6 mg/dL 1

Monitor calcium and phosphorus monthly for first 3 months, then every 3 months; measure PTH every 3 months for 6 months, then every 3 months thereafter. 1

Important Caveats

Assay Limitations

Current "intact PTH" assays measure both biologically active PTH (1-84) and inactive fragments (7-84), leading to overestimation of true PTH activity in CKD patients. 1, 3, 4 This is why target ranges are set higher than normal—attempting to maintain "normal" PTH levels risks adynamic bone disease. 1, 5

Evolving Guidelines

The 2017 KDIGO guidelines acknowledge that the optimal PTH level in CKD Stage 3b-4 is not known and recommend a less prescriptive approach than K/DOQI. 6, 7 KDIGO suggests evaluating patients with PTH "progressively rising or persistently above the upper normal limit" for modifiable factors rather than targeting specific ranges. 7 However, the K/DOQI target of 70-110 pg/mL remains the most specific guidance available for clinical practice. 1

Safety Considerations

• Hold active vitamin D if calcium exceeds 9.5 mg/dL or phosphorus exceeds 4.6 mg/dL 1
• Avoid calcium-based binders if calcium >10.2 mg/dL 1
• Recent evidence suggests sustained iPTH reduction may slow CKD progression, though this requires prospective validation 8

The K/DOQI target range provides actionable guidance for Stage 4 CKD, balancing the need to prevent both severe hyperparathyroidism and adynamic bone disease. 1